FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283804> ?p ?o ?g. }

• W4379283804 endingPage "2008" @default.
• W4379283804 startingPage "2008" @default.
• W4379283804 abstract "2008 Background: Patients (pts) with VHL disease are at risk for developing multiorgan tumors and cysts, including CNS HBs. The first-in-class hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan showed clinically meaningful antitumor activity in VHL disease–associated renal cell carcinoma (RCC) and other neoplasms in the ongoing, single-arm, phase 2 LITESPARK-004 study (NCT03401788). We present updated results for the subgroup of pts with CNS HBs. Methods: Adults with a VHL disease diagnosis based on germline VHL alteration, ≥1 measurable RCC tumor, no RCC tumor > 3 cm or other VHL tumor requiring immediate surgical intervention, no evidence of metastatic disease, no prior systemic anticancer treatment, and an ECOG PS score of 0 or 1 received belzutifan 120 mg orally once daily. End points evaluated in pts with CNS HBs included objective response rate (ORR), duration of response (DOR), time to response (TTR), and progression-free survival (PFS) per RECIST v1.1 by an independent review committee; linear growth rate (LGR); and safety. CNS HBs were assessed using 2 methodologies: 1) with measurable (≥1 cm) and/or nonmeasurable disease at baseline and with associated cysts, if present; and 2) with measurable disease at baseline, excluding associated cysts, if present, from the lesion measurement. Results: Of 61 enrolled pts, 50 (82%) had ≥1 CNS HB evaluable at baseline, and 22 (59%) pts had undergone ≥1 CNS-related surgery within 4 years prior to starting belzutifan treatment. As of the April 1, 2022 data cutoff date, median study follow-up for pts with CNS HBs was 38.0 mo (range, 36.1-46.1). ORR was 44% (n = 22; 95% CI, 30-59; 4 CRs, 18 PRs), and DCR was 90% (n = 45; 95% CI, 78-97). Median TTR was 5.4 mo (range, 2.3-33.1), and median DOR was not reached (NR; range, 3.7+ to 38.7+ mo). Median PFS was NR (95% CI, 38 mo to NR). After initiating belzutifan, median LGR for all evaluable pts was –1.6 mm/year (range, –7.0 to 3.1). Of all pts, 25/50 (50%) had ≥1 measurable CNS HBs, excluding any associated cysts. For these pts, ORR was 76% (95% CI, 55-91; 1 CR, 18 PRs), and DCR was 96% (n = 24; 95% CI, 80-100). Median TTR was 3.1 mo (range, 2.5-27.8), and median DOR was NR (range, 3.7+ to 38.7+ mo). Median PFS was NR (95% CI, 36 mo to NR). After initiating belzutifan, median LGR was –1.1 mm/year (range, –3.9 to –0.1). Of all pts, 1/50 (2%) underwent a CNS-related surgery after starting belzutifan. Two (3%) pts discontinued treatment due to treatment-related adverse events. Conclusions: With more than 3 years of treatment with belzutifan, consistent and durable antitumor activity was observed in pts with CNS HBs, which is consistent with findings in other VHL disease–associated neoplasms. Using different methodologies of assessing tumors, our data demonstrated that belzutifan induced the shrinkage of VHL disease–related CNS HBs with or without the presence of associated cysts. Clinical trial information: NCT03401788 ." @default.
• W4379283804 created "2023-06-05" @default.
• W4379283804 creator A5004009107 @default.
• W4379283804 creator A5004211801 @default.
• W4379283804 creator A5007689146 @default.
• W4379283804 creator A5022744341 @default.
• W4379283804 creator A5031748968 @default.
• W4379283804 creator A5033904513 @default.
• W4379283804 creator A5037818785 @default.
• W4379283804 creator A5038623685 @default.
• W4379283804 creator A5038992904 @default.
• W4379283804 creator A5053900181 @default.
• W4379283804 creator A5059690857 @default.
• W4379283804 creator A5066635849 @default.
• W4379283804 creator A5068785092 @default.
• W4379283804 creator A5074077037 @default.
• W4379283804 date "2023-06-01" @default.
• W4379283804 modified "2023-09-25" @default.
• W4379283804 title "Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study." @default.
• W4379283804 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.2008" @default.
• W4379283804 hasPublicationYear "2023" @default.
• W4379283804 type Work @default.
• W4379283804 citedByCount "0" @default.
• W4379283804 crossrefType "journal-article" @default.
• W4379283804 hasAuthorship W4379283804A5004009107 @default.
• W4379283804 hasAuthorship W4379283804A5004211801 @default.
• W4379283804 hasAuthorship W4379283804A5007689146 @default.
• W4379283804 hasAuthorship W4379283804A5022744341 @default.
• W4379283804 hasAuthorship W4379283804A5031748968 @default.
• W4379283804 hasAuthorship W4379283804A5033904513 @default.
• W4379283804 hasAuthorship W4379283804A5037818785 @default.
• W4379283804 hasAuthorship W4379283804A5038623685 @default.
• W4379283804 hasAuthorship W4379283804A5038992904 @default.
• W4379283804 hasAuthorship W4379283804A5053900181 @default.
• W4379283804 hasAuthorship W4379283804A5059690857 @default.
• W4379283804 hasAuthorship W4379283804A5066635849 @default.
• W4379283804 hasAuthorship W4379283804A5068785092 @default.
• W4379283804 hasAuthorship W4379283804A5074077037 @default.
• W4379283804 hasConcept C126322002 @default.
• W4379283804 hasConcept C141071460 @default.
• W4379283804 hasConcept C143998085 @default.
• W4379283804 hasConcept C2777472916 @default.
• W4379283804 hasConcept C2778822529 @default.
• W4379283804 hasConcept C2778886567 @default.
• W4379283804 hasConcept C2779134260 @default.
• W4379283804 hasConcept C71924100 @default.
• W4379283804 hasConcept C90924648 @default.
• W4379283804 hasConceptScore W4379283804C126322002 @default.
• W4379283804 hasConceptScore W4379283804C141071460 @default.
• W4379283804 hasConceptScore W4379283804C143998085 @default.
• W4379283804 hasConceptScore W4379283804C2777472916 @default.
• W4379283804 hasConceptScore W4379283804C2778822529 @default.
• W4379283804 hasConceptScore W4379283804C2778886567 @default.
• W4379283804 hasConceptScore W4379283804C2779134260 @default.
• W4379283804 hasConceptScore W4379283804C71924100 @default.
• W4379283804 hasConceptScore W4379283804C90924648 @default.
• W4379283804 hasIssue "16_suppl" @default.
• W4379283804 hasLocation W43792838041 @default.
• W4379283804 hasOpenAccess W4379283804 @default.
• W4379283804 hasPrimaryLocation W43792838041 @default.
• W4379283804 hasRelatedWork W1748266548 @default.
• W4379283804 hasRelatedWork W1997507573 @default.
• W4379283804 hasRelatedWork W2002120878 @default.
• W4379283804 hasRelatedWork W2003938723 @default.
• W4379283804 hasRelatedWork W2047967234 @default.
• W4379283804 hasRelatedWork W2439875401 @default.
• W4379283804 hasRelatedWork W2472578570 @default.
• W4379283804 hasRelatedWork W2615542546 @default.
• W4379283804 hasRelatedWork W3159453953 @default.
• W4379283804 hasRelatedWork W3163179811 @default.
• W4379283804 hasVolume "41" @default.
• W4379283804 isParatext "false" @default.
• W4379283804 isRetracted "false" @default.
• W4379283804 workType "article" @default.